Evotec AG, which operates a global drug discovery business, is proposing to acquire Cyprotex Plc, a London-listed contract research organisation, which has developed a service for measuring the performance of drugs under development called ADME-Tox. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
